Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype

Clinical Pharmacology and Therapeutics

Volumn 71, Issue 1, 2002, Pages 89-98

  Yasar, Ümit ^a,b   Forslund Bergengren, Cecilia ^a,b   Tybring, Gunnel ^a,b   Dorado, Pedro ^a,b   Llerena, Adrián ^a,b   Sjöqvist, Folke ^a,b   Eliasson, Erik ^a,b   Dahl, Marja Liisa ^a,b,c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF EXTREMADURA   (Spain)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; CYTOCHROME P450 2C9; DRUG METABOLITE; L 158; LOSARTAN POTASSIUM; UNCLASSIFIED DRUG;

ADULT; ALLELE; AREA UNDER THE CURVE; ARTICLE; CORRELATION FUNCTION; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG URINE LEVEL; ENZYME ACTIVITY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; SPAIN; SWEDEN;

ADMINISTRATION, ORAL; ADULT; ALLELES; ANTIHYPERTENSIVE AGENTS; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENOTYPE; HUMANS; IMIDAZOLES; LOSARTAN; MALE; MIDDLE AGED; PHARMACOGENETICS; SPAIN; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES; SWEDEN; TETRAZOLES;

EID: 0036161753     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2002.121216     Document Type: Article

References (39)

1. Cytochrome P4502C9: An enzyme of major importance in human drug metabolism
2. Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele
3. Impact of CYP2C9 genotype on glibenclamide pharmacokinetics and pharmacodynamics in healthy volunteers
4. Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily
5. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9
6. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism
7. Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a Black African population
8. Validation of methods for CYP2C9 genotyping: Frequencies of mutant alleles in a Swedish population
9. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement
10. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy
11. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
12. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: Studies in stereoselective hydroxylation and population pharmacokinetics
13. A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin
14. Genetic polymorphism of the CYP2C subfamily and excessive serum phenytoin concentration with central nervous system intoxication
15. Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans
16. Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: Genetic analysis of the CYP2C9 locus
17. Polymorphic hydroxylation of debrisoquine in man
18. Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in man
19. Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers
20. Tolbutamide hydroxylation in humans: Lack of bimodality in 106 healthy subjects
21. Use of tolbutamide as a substrate probe for human hepatic cytochrome P450 2C9
22. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin
23. Limited value of the urinary phenytoin metabolic ratio for the assessment of cytochrome P4502C9 activity in vivo
24. Angiotensin II receptors and angiotensin II receptor antagonists
25. Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes: Role of cytochrome P4502C and 3A subfamily members
26. Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes: Role of cytochrome P4503A(4) in formation of the active metabolite EXP3174
27. The role of CYP2C9 polymorphism in losartan oxidation
28. Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174
29. Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers
30. An improved method for the simultaneous determination of losartan and its major metabolite, EXP3174, in human plasma and urine by high-performance liquid chromatography with fluorescence detection
31. Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E-3174
32. Correlation of human cytochrome P4502C substrate specificities with primary structure: Warfarin as a probe
33. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population
34. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: Comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype
35. Lack of polymorphism of the conversion of losartan to its active metabolite E-3174 in extensive and poor metabolizers of debrisoquine (cytochrome P450 2D6) and mephenytoin (cytochrome P450 2C19)
36. The effects of fluvastatin, a CYP2C9 inhibitor, on losartan pharmacokinetics in healthy volunteers
37. Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist
38. CYP2C9 Ile359 and Leu359 variants: Enzyme kinetic study with seven substrates
39. The metabolism of DuP 753, a nonpeptide angiotensin II receptor antagonist, by rat, monkey, and human liver slices